Related Experiment Video

Updated: Jan 1, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.1K

β-TRCP-mediated AEBP2 ubiquitination and destruction controls cisplatin resistance in ovarian cancer

Qin Zhang1, Wei Wang2, Qun Gao3

  • 1Obstetrics and Gynecology Department of the First People's Hospital of Jing Zhou, The First Clinical Medical College of Yangtze University, China.

Biochemical and Biophysical Research Communications
|December 23, 2019
PubMed

Insights

AEBP2 promotes ovarian cancer growth and cisplatin resistance. Inhibiting the β-TRCP-AEBP2 pathway may offer new ovarian cancer treatments.

Area of Science:

  • Molecular Biology
  • Cancer Biology
  • Epigenetics

Background:

  • AEBP2, a zinc finger protein, is linked to the Polycomb Repression Complex 2 (PRC2) and neural crest cell development.
  • Its role in cancer and its own regulation are largely unexplored.

Purpose of the Study:

  • To investigate the function of AEBP2 in ovarian cancer.
  • To elucidate the regulatory mechanisms of AEBP2 in cancer cells.

Main Methods:

  • Genetic knockout of AEBP2 in ovarian cancer cells.
  • Analysis of AEBP2 ubiquitylation and proteasomal degradation.
  • Assessment of cisplatin sensitivity in AEBP2-modified cells.

Main Results:

  • AEBP2 knockout inhibited ovarian cancer cell proliferation and enhanced cisplatin sensitivity.
  • AEBP2 possesses a non-canonical phosphodegron targeted by SCF β-TrCP ubiquitin ligase.
  • Impaired AEBP2 degradation led to cisplatin resistance in ovarian cancer.

Conclusions:

  • AEBP2 plays an oncogenic role in ovarian cancer.
  • Targeting the β-TRCP-AEBP2 axis presents a potential therapeutic strategy for ovarian cancer.
Keywords:
AEBP2Ovarian cancerUbiquitinationβ-TrCP

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

9.0K
Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.5K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.1K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.1K